T-Cell Dysfunction As a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Feb 6

PMID 33546277

Citations 17

Authors

Valerie Janelle

Jean-Sebastien Delisle

Affiliations

Soon will be listed here.

Abstract

Over the last decades, cellular immunotherapy has revealed its curative potential. However, inherent physiological characteristics of immune cells can limit the potency of this approach. Best defined in T cells, dysfunction associated with terminal differentiation, exhaustion, senescence, and activation-induced cell death, undermine adoptive cell therapies. In this review, we concentrate on how the multiple mechanisms that articulate the various forms of immune dysfunction impact cellular therapies primarily involving conventional T cells, but also other lymphoid subtypes. The repercussions of immune cell dysfunction across the full life cycle of cell therapy, from the source material, during manufacturing, and after adoptive transfer, are discussed, with an emphasis on strategies used during ex vivo manipulations to limit T-cell dysfunction. Applicable to cellular products prepared from native and unmodified immune cells, as well as genetically engineered therapeutics, the understanding and potential modulation of dysfunctional features are key to the development of improved cellular immunotherapies.

Citing Articles

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J Nat Commun. 2025; 16(1):649.

PMID: 39809767 PMC: 11733228. DOI: 10.1038/s41467-024-55420-6.

Alginate-based artificial antigen presenting cells expand functional CD8 T cells with memory characteristics for adoptive cell therapy.

Omotoso M, Est-Witte S, Shannon S, Li S, Nair N, Neshat S Biomaterials. 2024; 313:122773.

PMID: 39217794 PMC: 11423771. DOI: 10.1016/j.biomaterials.2024.122773.

Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1.

Yado S, Dassa B, Zoabi R, Reich-Zeliger S, Friedman N, Geiger B J Immunother Cancer. 2024; 12(6).

PMID: 38866588 PMC: 11177851. DOI: 10.1136/jitc-2024-009011.

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

Klobuch S, Seijkens T, Schumacher T, Haanen J Nat Rev Clin Oncol. 2024; 21(3):173-184.

PMID: 38191921 DOI: 10.1038/s41571-023-00848-w.

Acellular scaffold-based approach for in situ genetic engineering of host T-cells in solid tumor immunotherapy.

Dandia H, Pillai M, Sharma D, Suvarna M, Dalal N, Madhok A Mil Med Res. 2024; 11(1):3.

PMID: 38173045 PMC: 10765574. DOI: 10.1186/s40779-023-00503-6.

References

Oei V, Siernicka M, Graczyk-Jarzynka A, Hoel H, Yang W, Palacios D . Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018; 6(4):467-480. DOI: 10.1158/2326-6066.CIR-17-0207. View

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

Roberts A, Devadas S, Zhang X, Zhang L, Keegan A, Greeneltch K . The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res. 2004; 28(3):285-93. DOI: 10.1385/IR:28:3:285. View

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

Ghassemi S, Nunez-Cruz S, OConnor R, Fraietta J, Patel P, Scholler J . Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunol Res. 2018; 6(9):1100-1109. PMC: 8274631. DOI: 10.1158/2326-6066.CIR-17-0405. View

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P . CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998; 188(8):1521-8. PMC: 2213408. DOI: 10.1084/jem.188.8.1521. View

Ben-Porath I, Weinberg R . When cells get stressed: an integrative view of cellular senescence. J Clin Invest. 2004; 113(1):8-13. PMC: 300889. DOI: 10.1172/JCI20663. View

10.

Zheng L, Fisher G, Miller R, Peschon J, Lynch D, Lenardo M . Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995; 377(6547):348-51. DOI: 10.1038/377348a0. View

11.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

12.

Suda T, Takahashi T, Golstein P, Nagata S . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993; 75(6):1169-78. DOI: 10.1016/0092-8674(93)90326-l. View

13.

Exley M, Wilson S, Balk S . Isolation and Functional Use of Human NKT Cells. Curr Protoc Immunol. 2017; 119:14.11.1-14.11.20. DOI: 10.1002/cpim.33. View

14.

Yang Y, Badeti S, Tseng H, Ma M, Liu T, Jiang J . Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways. Mol Ther Methods Clin Dev. 2020; 18:428-445. PMC: 7364029. DOI: 10.1016/j.omtm.2020.06.014. View

15.

Fearon D, Manders P, Wagner S . Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science. 2001; 293(5528):248-50. DOI: 10.1126/science.1062589. View

16.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

17.

Schmitz M . Activation of T cells: releasing the brakes by proteolytic elimination of Cbl-b. Sci Signal. 2009; 2(76):pe38. DOI: 10.1126/scisignal.276pe38. View

18.

Chapuis A, Thompson J, Margolin K, Rodmyre R, Lai I, Dowdy K . Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109(12):4592-7. PMC: 3311364. DOI: 10.1073/pnas.1113748109. View

19.

Bernink J, Peters C, Munneke M, Te Velde A, Meijer S, Weijer K . Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013; 14(3):221-9. DOI: 10.1038/ni.2534. View

20.

Buonocore S, Ahern P, Uhlig H, Ivanov I, Littman D, Maloy K . Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 2010; 464(7293):1371-5. PMC: 3796764. DOI: 10.1038/nature08949. View